X-Chem Revenue and Competitors

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • X-Chem's estimated annual revenue is currently $32.5M per year.(i)
  • X-Chem's estimated revenue per employee is $155,000

Employee Data

  • X-Chem has 210 Employees.(i)
  • X-Chem grew their employee count by 2% last year.

X-Chem's People

CEOReveal Email/Phone
SVP, Alliance Management and InnovationReveal Email/Phone
VP ChemistryReveal Email/Phone
VP, Business Development - UK/EuropeReveal Email/Phone
SVPReveal Email/Phone
SVP and General ManagerReveal Email/Phone
Executive Director ChemistryReveal Email/Phone
Director Finance, USAReveal Email/Phone
Senior Director, Library ChemistryReveal Email/Phone
Associate DirectorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

What Is X-Chem?

X-Chem, Inc. is a privately held biotechnology company based in Waltham, Massachusetts, established in 2009 to apply its innovative drug discovery capabilities to the generation of novel small molecule therapeutics. Our chemical strategy can be applied broadly to most targets in any therapeutic area, including the most challenging ones. We have built a strong team of leading experts with proven track records in innovative drug discovery and biotechnology partnering. We have demonstrated our success both internally and with external partnerships by tackling some of the most difficult, intractable targets such as: -protein:protein interactions (PPI) -antibacterial targets -ubiquitin ligases -epigenetic targets -GPCRs We have established collaborations with eight of the leading pharmaceutical companies in the world, including among others: Roche, AstraZeneca, Bayer and Pfizer. We also have partnerships with top tier biotechnology companies, academic centers and non-profit institutions. We have generated novel lead compounds against dozens of high-value therapeutic targets, leading to licensing of multiple lead series by our partners. History The company was founded in 2009 by industry veterans Richard Wagner, Brant Binder and Gordon Binder. In 2010, X-Chem and Pharmaceutical Product Development, LLC (PPD) formed a strategic partnership, including an investment by PPD. In September 2014, PPD exercised its option to acquire all remaining interests in X-Chem, while retaining the company's management, scientific staff and biotechnology business model. The company was spun out as an independent company in 2015 under the ownership of the private equity firms the Carlyle Group, and Hellman and Friedman.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





X-Chem News

2022-04-17 - Cannabis Leader Kiva Confections Partners with Musician ...

The Lost Farm Dragonfruit x Grape Pie Cookies Gummies will be available for ... with the second installment, Blood Orange x Chem Dog Chews,...

2022-04-13 - Philanthropic investment accelerates research, renames ...

In recognition of her investment, Stanford ChEM-H is changing its ... of the Wu Tsai Neurosciences Institute, Stanford Bio-X, and ChEM-H.

2022-04-13 - X-Chem's New AI-Powered Ecosystem to Accelerate Drug ...

With XD3, X-Chem's scientists seamlessly combine DEL, medicinal chemistry and AI to deliver enhanced small molecule drug discovery services...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding